InsiderTrades

Form 4 for TVTX Travere Therapeutics, Inc.

Accepted 2024-11-25 00:00:00 ET · period of report 2024-11-25 · accession 0001415889-24-027672 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2024-11-25 2024-11-25 TVTX Calvin Sandra SVP, CAO M - OptEx $12.67 +15.0K 67.0K +29% +$190.1K
D 2024-11-25 2024-11-25 TVTX Calvin Sandra SVP, CAO S - Sale+OE $18.30 -12.1K 54.9K -18% -$221.2K
D 2024-11-25 2024-11-25 TVTX Calvin Sandra SVP, CAO M - OptEx $0.00 -15.0K 15.0K -50% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-11-25 M A 15,000 $12.67 67,017 D — —
2 Common Common Stock 2024-11-25 S D 12,090 $18.30 54,927 D — — (F1) Represents the number of shares required to be sold by the Reporting Person in order to cover the tax withholding obligation and payment of the exercise price in connection with the partial exercise of a stock option granted to the Reporting Person on January 2, 2015 with an upcoming expiration date of January 2, 2025. (F2) The weighted average sale price for the transaction reported was $18.3009, and the range of prices were between $18.27 and $18.37. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
3 Derivative Employee stock option (right to buy) 2024-11-25 M D 15,000 $0.00 15,000 D $12.67 · — to 2025-01-02 15,000 Common Stock (F3) The stock option is fully vested and exercisable.